Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in MiceAndrea J. Pruijssers, Timothy P. Sheahan, Jason K. Perry et al.|Cell Reports|2020Cited by 541
Prodrugs of a 1′-CN-4-Aza-7,9-dideazaadenosine <i>C</i>-Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSVRichard L. Mackman, Tomáš Cihlář, Hon C. Hui et al.|Journal of Medicinal Chemistry|2021Cited by 90
Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in miceAlexandra Schäfer, Timothy P. Sheahan, David R. Martinez et al.|Science Translational Medicine|2022Cited by 83
Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green MonkeysRichard L. Mackman, Tomáš Cihlář, Rao Kalla et al.|Journal of Medicinal Chemistry|2023Cited by 63
Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in miceAndrea J. Pruijssers, Timothy P. Sheahan, Amelia S. George et al.|bioRxiv (Cold Spring Harbor Laboratory)|2020Cited by 36